Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims

Yahoo Finance Video
8,486 次觀看・1 個月前

Shares of Cassava Sciences (SAVA) are falling after reaching a settlement with US securities regulators. This comes after the pharmaceutical company was charged for misleading claims about an Alzheimer's clinical trial.

Market Domination Hosts Julie Hyman and Josh Lipton report more on the story.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Melanie Riehl